Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Bolsa de Madrid  >  Pharma Mar SA    PHM   ES0169501030

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Pharma Mar : Phase III trial with Zepsyre® in small-cell lung cancer (ATLANTIS) to continue on the basis of positive recommendation by IDMC

share with twitter share with LinkedIn share with facebook
share via e-mail
11/15/2017 | 08:35am CET
Phase III trial with Zepsyre® in small-cell lung cancer (ATLANTIS) to continue on the basis of positive recommendation by IDMC Madrid, 15th November 2017 - PharmaMar (MSE:PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has notified the Company of its recommendation that the Phase III (ATLANTIS) trial currently under way with Zepsyre® (PM1183) in combination with doxorubicin in small-cell lung cancer patients should continue without any changes.

The IDMC's recommendation came after an analysis of the safety data obtained with the first 150 patients treated in the trial. This pivotal randomised Phase III trial assesses the efficacy of PM1183 in combination compared with the standard treatment for this indication: investigator's choice of either Topotecan or CAV (cyclophosphamide, doxorubicin, and vincristine). The trial is expected to enroll approximately 600 patients and over half are already included.

About Zepsyre®

Zepsyre® is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is involved in the transcription process that is over-activated in tumors with transcription addiction. The antitumor efficacy of lurbinectedin is being investigated in various types of solid tumors, including a Phase III study for platinum-resistant ovarian cancer, a Phase II study for BRCA 1 and BRCA 2-associated metastatic breast cancer and a Phase III study for small cell lung cancer.

About small-cell lung cancer

SCLC is a very aggressive cancer that usually presents with distant metastases and has already spread at the time of diagnosis, thus limiting the role of traditional approaches and posing a worse prognosis compared to other lung cancer types. The 5-year survival rate is about 5%i. About 18% of all the lung cancer cases diagnosed are SCLC, and only in the US more than 34,000 new cases are recorded every year. This tumor is strongly associated with tobacco smoking, posing an important public health problemii. After failure to treatment with a platinum-based therapy in first line, the therapeutic alternatives are very limited, and the approval of the last drug for this disease took place 20 years ago.

About PharmaMar

Headquartered in Madrid, PharmaMar is a leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has other clinical-stage programs under development for several types of solid and hematological cancers, Zepsyre® (PM1183), plitidepsin, PM184 and PM14. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium, Austria and the United States. PharmaMar fully owns other companies: GENOMICA, a leading

molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at www.pharmamar.com.


This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

Media Contact:

Alfonso Ortín - Communications Director [email protected] Mobile: + 34609493127

Paula Fernández - Media Relations Manager [email protected] Mobile: +34 638796215 Phone: +34 918466000

Investor Relations:

Phone: +34 914444500

Or please visit our website at www.pharmamar.com



Pharma Mar SA published this content on 15 November 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 15 November 2017 07:34:01 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PHARMA MAR SA
11/15 PHARMA MAR : Phase III trial with Zepsyre® in small-cell lung cancer (ATLANTIS) ..
11/15 R&D : new licenses, patents and registered trademarks
11/14 PHARMA MAR : GENOMICA Receives Authorization for the Commercialization of its Di..
11/14 PHARMA MAR : PharmaMar to present at the Stifel 2017 Healthcare Conference
11/14 PHARMA MAR : Announcements of public presentations and meetings
11/13 PHARMA MAR : PharmaMar presents positive results from a Phase II study of lurbin..
11/08 R&D : new licenses, patents and registered trademarks
11/07 PHARMA MAR : PharmaMar and Boryung Pharm sign a licensing agreement for Zepsyre®..
11/04 PHARMA MAR : PharmaMar announces partnership with 8th National Race to End Women..
11/03 PHARMA MAR : PharmaMar will present at ESGO new data on Yondelis® for gynecologi..
More news
News from SeekingAlpha
11/16 Pharma Mar (PHMMF) Presents At Stifel 2017 Healthcare Conference - Slideshow
08/13 3 THINGS IN BIOTECH YOU SHOULD LEARN : August 13, 2017
03/16 Talking With PharmaMar's Management About Its Upcoming Pivotal Year
Financials (€)
Sales 2017 175 M
EBIT 2017 -17,2 M
Net income 2017 -13,6 M
Debt 2017 62,7 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 3,39x
EV / Sales 2018 3,12x
Capitalization 532 M
Duration : Period :
Pharma Mar SA Technical Analysis Chart | PHM | ES0169501030 | 4-Traders
Technical analysis trends PHARMA MAR SA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 5,26 €
Spread / Average Target 120%
EPS Revisions
José Maria Fernández de Sousa-Faro Executive Chairman, President & CEO
Pascal M. Besman Chief Operating Officer
Maria Luisa de Francia Chief Financial Officer
Nadia Badri Vice President-Medical Affairs
Pedro Fernández Puentes Executive Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
PHARMA MAR SA-11.81%630
BIOGEN18.26%65 516
CSL LIMITED43.07%49 706
GRIFOLS SA33.08%18 690